Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9
T
TYRA• Phase 2 SURF302 data presentation scheduled
Tyra Biosciences scheduled a Sept. 9, 2026 conference call to present initial Phase 2 results for oral dabogratinib.
Data will be presented in the future, covering the SURF302 study in intermediate-risk non-muscle invasive bladder cancer.
The update signals an early readout for a key clinical program targeting FGFR biology, a potential driver of future development decisions.
OTF
•
Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9 - TYRA News | Rallies
